Successes and Failures of the Live-attenuated Influenza Vaccine: Can We Do Better?

• Type of Material: Article
• Authors: Laura Matrajt, Fred Hutchinson Cancer Research Center; M. Elizabeth Halloran, Fred Hutchinson Cancer Research Center; Rustom Antia, Emory University
• Language: English
• Date: 2020-03-03
• Publisher: Oxford Academic Press
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/cid/ciz358
• Title of Journal or Parent Work: Clinical Infectious Diseases
• Volume: 70
• Issue: 6
• Start Page: 1029
• End Page: 1037
• Grant/Funding Information: This work was supported by the National Institute of General Medical Sciences (grant number U54GM111274) and the National Institute of Allergy and Infectious Disease (grant number U19 AI117891) of the National Institutes of Health.
• Keywords: vaccine; mathematical model; Influenza Vaccines; Vaccines, Attenuated; Influenza, Human; live-attenuated influenza vaccine (LAIV); Child; influenza; Humans
• Research Categories: Biology, Biostatistics; Health Sciences, Immunology; Health Sciences, Epidemiology; Health Sciences, Public Health

Abstract

Background The effectiveness of the live-attenuated influenza vaccine (LAIV) can vary widely, ranging from 0% to 50%. The reasons for these discrepancies remain largely unclear. Methods We use mathematical models to explore how the efficacy of LAIV is affected by the degree of mismatch with the currently circulating influenza strain and interference with pre-existing immunity. The models incorporate 3 key antigenic distances: the distances between the vaccine strain, pre-existing immunity, and the challenge strain. Results Our models show that an LAIV that is matched with the currently circulating strain is likely to have only modest efficacy. Our results suggest that the efficacy of the vaccine would be increased (optimized) if, rather than being matched to the circulating strain, it is antigenically slightly further from pre-existing immunity than the circulating strain. The models also suggest 2 regimes in which LAIV that is matched to circulating strains may be protective: in children before they have built immunity to circulating strains and in response to novel strains (such as antigenic shifts) which are at substantial antigenic distance from previously circulating strains. We provide an explanation for the variation in vaccine effectiveness between studies and countries of vaccine effectiveness observed during the 2014–2015 influenza season. Conclusions LAIV is offered to children across the world; however, its effectiveness significantly varies between studies. Here, we propose a mechanistic explanation to understand these differences. We further propose a way to select the LAIV strain that would have a higher chance of being protective.